COMP <GO>
CLGN vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
CollPlant Biotechnologies Ltd (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: CLGN 2
— MRK 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $4.14 (-6.02%) • MKT CAP: $12.7M
roic
-35.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLGN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLGN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.80% | 74.80% | -10.00 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.42% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 1.30% | +178.70 | CLGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.19 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.3 | 51.7 | +8.60 | CLGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.7M | $361.02B | -$361.01B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLGN REV | MRK REV | CLGN GROSS % | MRK GROSS % | CLGN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.4M | $65.01B | 64.8% | 74.8% | -$9.4M | $12.36B |
| FY 2024 | $515.0K | $64.17B | -50.0% | 76.3% | -$14.6M | $18.10B |
| FY 2023 | $11.0M | $60.12B | — | — | -$2.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLGN // BETA —
MRK // BETA 0.92